|
Published by: Kalorama Information
Published: Jan. 1, 1997 - 194 Pages Now 50% off the original sale price of $3,250.
Table of Contents
Chapter One: Executive Summary
- Introduction and Overview
- Definition and Scope
- Primary Osteoporosis
- Secondary Osteoporosis
- Risk Factors for Developing Osteoporosis
- Importance of Both Diagnostics and Therapeutics in the Management of Osteoporosis
- Evolution of Market Awareness and Market Dynamics
- Demographics as a Driving Force
- Osteoporosis Disease Management: Diagnostic and Therapeutic Products
- Osteoporosis Diagnostics
- Overview
- Densitometry
- Competitive Environment: Major Suppliers of Densitometers
- Biochemical Markers
- Bone Resorption
- Bone Formation
- Competitive Environment: Major Suppliers of Marker Assays
- Osteoporosis Diagnostics in Development
- Competitive Environment: Major Suppliers of Osteoporosis Diagnostics on the Market
- Osteoporosis Therapeutics
- Overview
- Product Categories
- Hormone Replacement Therapy
- Calcitonin
- Bisphosphonates
- Bone Formation Agents
- Fluorides
- Anabolic Steroids
- Calcium
- Vitamin D
- Osteoporosis Therapeutics in Development
- New Products
- Combination Therapy
- The Market
- Market Size (Revenue) and Forecast
- Issues and Trends
- Evolving Role of Key Market Constituents
- Patients
- Managed Care Organizations
- Physicians
- Pharmacies
- Insurance Companies
- Medicare Administration
- Women's Health Advocacy Organizations
- Increased Demand for Bone Density Tests
- Lack of Guidelines for Osteoporosis Screening
- Availability of Diagnostic Equipment
- Agreements Between Pharmaceutical and Diagnostic Companies
- Cost of Various Treatments for Osteoporosis
- Scope and Methodology
Chapter Two: Introduction to Osteoporosis
- Overview
- Bone Biology
- Osteoporosis Disease Management
- Overview
- Incidence and Prevalence
- Cost of Osteoporosis-Related Fractures
- Pathogenesis of Osteoporosis
- Primary Osteoporosis
- Secondary Osteoporosis
- Risk Factors for Developing Osteoporosis
- Genetic Factors
- Hormone-Related Factors
- Lifestyle-Related Factors
- Nutrition-Related Disorders
- Osteoporosis Diagnostics
- Overview
- Bone Densitometry
- Biochemical Markers
- Bone Resorption
- Osteoporosis Therapeutics
- Overview
- Antiresorptive Agents
- Hormone Replacement Therapy (HRT)
- Combined Hormone Replacement Products
- Calcitonin
- Bisphosphonates
- Bone Formation Agents
- Fluorides
- Anabolic Steroids
- Parathyroid Hormone
- Combination Therapy and Other Agents
- Combination Therapy
- Calcium
- Vitamin D
Chapter Three: Diagnostic and Therapeutic Products
- Osteoporosis Diagnostics: Product Overview
- Densitometry as a Diagnostic Tool
- Clinical Indications
- BMD Techniques
- Diagnostic Criteria and BMD Values
- Cost of Examinations
- Major Suppliers of Densitometers
- Biochemical Markers
- Major Suppliers of Marker Assays
- Perceptions of Biochemical Markers
- Osteoporosis Therapeutics
- Product Overview
- Bone Mass and Fracture Risk
- BMD Values and Therapeutics
- Osteoporosis Therapeutics For Men
- Calcium and Vitamin D Supplementation
- Efficacy
- Side Effects
- Contraindications
- Duration of Treatment
- Estrogen Replacement Therapy
- Efficacy
- Side Effects
- Contraindications
- Duration of Treatment
- Bisphosphonates
- Efficacy
- Side Effects
- Contraindications
- Duration of Treatment
- Calcitonin
- Efficacy
- Contraindications
- Duration of Treatment
- Other Off-Label Therapeutics
- Sodium Fluoride
- Anabolic Steroids
- Concomitant Use of Therapeutic Agents
- Cost of Various Treatments for Osteoporosis
- Osteoporosis Diagnostics and Therapeutics in Development
- Overview
- Osteoporosis Diagnostics in Development
- Ultrasound Densitometers
- Biochemical Markers
- Osteoporosis Therapeutics in Development
- Anti-Estrogen Therapeutics
- Parathryroid Hormone
- Sodium Fluoride
- Directions for Future Research
Chapter Four: Issues and Trends
- Managed Care
- Emphasis on Disease Prevention
- Impact on Osteoporosis
- Osteoporosis Screening
- Medicare and Managed Care
- Growing Enrollment in Managed Care
- Demographics
- Population of Elderly Continues to Increase
- Increase in Elderly Population Increases Number of Osteoporosis Fractures
- Increase in Elderly Population Increases Osteoporosis Costs
- Acute-Care Hospital Costs
- Long-Term Care Costs
- Research Essential To Determine Optimal Prevention and Effective Care Strategies
- Therapeutics Drive Demand for Bone Density Tests
- Relating Therapeutics to Diagnostics
- Availability of Diagnostic Equipment
- Interpreting Test Results: Performance Standards
- Agreements Between Pharmaceutical and Diagnostic Companies
- Merck Promotes Bone Density Examinations
- Suitability of Biochemical Markers in Managing Osteoporosis
- Hormone Replacement Therapy as a Prophylactic Against Osteoporosis
- The Compliance Issue
- National Focus On Women's Health
- Older Women
- Future Trends in the Management of Osteoporosis
- Ultrasound Diagnostic Densitometry
- Lunar's Achilles Ultrasound Densitometer
- Genome Science and Therapeutics
- Research Focuses on Gene-Based Drug Discovery
- SmithKline Beecham's Gene Discovery
- The Osteoporosis Gene (the VDR Gene)
Chapter Five: The Market
- Disease Management
- Scope and Methodology
- Demographics Driving Market
- Market Overview
- Total Market Size And Forecast
- Osteoporosis Diagnostics
- Biochemical Markers
- Market Size and Forecast
- Major Products and Competitors
- Trends
- Bone Densitometers
- Market Size and Forecast
- Major Products and Competitors
- Trends
- Osteoporosis Therapeutics
- Hormone Replacement Therapy
- Market Size and Forecast
- Major Products and Competitors
- Trends
- Non-hormonal Therapeutics
- Market Size and Forecast
- Major Products and Competitors
- Trends
Chapter Six: Company Profiles
- Overview of Diagnostics Manufacturers
- Overview of Therapeutics Manufacturers
- Abbott Laboratories
- History and Lines of Business
- Financial Information
- Analysis
- Osteoporosis Therapeutics
- Research and Development
- Corporate Strategies
- Ariad Pharmaceuticals, Inc.
- History and Lines of Business
- Financial Information
- Analysis
- Signal Transduction in Cells and Osteoporosis
- Bristol-Myers Squibb Co.
- History and Lines of Business
- Financial Information
- Analysis
- Osteoporosis Product
- Research and Development
- Hoffman-La Roche Inc.
- History and Lines of Business
- Financial Information
- Analysis
- Osteoporosis Therapeutic Product
- Research and Development
- Hologic, Inc.
- History and Lines of Business
- Financial Information
- Analysis
- Densitometry Products
- Research and Development
- Corporate Strategies
- Human Genome Sciences, Inc.
- History and Lines of Business
- Financial Information
- Analysis
- Gene Discovery and Osteoporosis
- Incyte Pharmaceuticals, Inc.
- History and Lines of Business
- Financial Information
- Analysis
- Gene Sequencing and Osteoporosis
- Ligand Pharmaceuticals, Inc.
- History and Lines of Business
- Financial Information
- Analysis
- Intracellular Receptor Technology and Osteoporosis Products
- Lunar Corp.
- History and Lines of Business
- Financial Information
- Analysis
- Bone Densitometry Products
- Research and Development
- Corporate Strategies
- Eli Lilly and Co.
- History and Lines of Business
- Financial Information
- Analysis
- Osteoporosis Therapeutics
- Merck & Co., Inc.
- Lines of Business
- Financial Information
- Analysis
- Osteoporosis Product
- Research and Development
- Corporate Strategies
- Metra Biosystems, Inc.
- History and Lines of Business
- Financial Information
- Analysis
- Osteoporosis Products
- Research and Development
- Corporation Strategies
- Norland Medical Systems, Inc.
- History and Lines of Business
- Financial Information
- Analysis
- Densitometry Products
- Research and Development
- Corporate Strategies
- Novartis, Ltd.
- Lines of Business
- Financial Information
- Analysis
- Osteoporosis Products
- Research and Development
- Ostex International, Inc.
- History and Lines of Business
- Financial Information
- Analysis
- Osteoporosis Product
- Research and Development
- Corporate Strategies
- Pharmacia & Upjohn Inc.
- History and Lines of Business
- Financial Information
- Corporate Analysis
- Osteoporosis Therapeutic
- Rhone-Poulenc Rorer Inc.
- History and Lines of Business
- Financial Information
- Analysis
- Osteoporosis Therapeutic
- Research and Development
- SmithKline Beecham Corp.
- History and Lines of Business
- Financial Information
- Analysis
- Osteoporosis Therapeutics
- Research and Development
- Unigene Laboratories Inc.
- History and Lines of Business
- Financial Information
- Analysis
- Osteoporosis Therapeutics
- Research and Development
- Warner-Lambert Co.
- History and Lines of Business
- Financial Information
- Analysis
- Osteoporosis Therapeutics
- Corporate Strategies
- Wyeth-Ayerst Laboratories (Division of American Home Products Corp.)
- History and Lines of Business
- Financial Information
- Analysis
- Osteoporosis Therapeutics
Appendix A: Glossary of Terms
Appendix B: Company Names and Addresses
AbstractOsteoporosis affects nearly half of all people women and men over the age of 70. The Kalorama Information study provides estimates for current market revenues and forecasts for osteoporosis diagnostics and therapeutics through 2001 are provided. It also profiles pharmaceutical, diagnostic, and biotechnology companies involved in the discovery, manufacture, and distribution of osteoporosis diagnostics and therapeutics. These range from giants such as Abbott and Eli Lilly to niche players including ARIAD, Human Genome Sciences, and Unigene.
Get Full Details About This Report >>
|
